AEON Biopharma Inc (AEON) Stock Analysis
Verdict: AVOID
Severe cash burn ($17.3M/yr) and ~2 months of liquidity force imminent dilution risk, overshadowing biosimilar ABP-450 pipeline progress.
Investment score: 20/100
Analysis as of
Is AEON Biopharma Inc stock worth reviewing? AI model thesis
The model assesses AEON as an AVOID. Immediate cash insolvency risk and structural balance sheet impairment overpower biosimilar analytical milestones for ABP-450.
7-factor investment score
- Valuation: 15/100 (weight 20%)
- Financial Health: 5/100 (weight 15%)
- Technical Momentum: 15/100 (weight 15%)
- Earnings Quality: 20/100 (weight 15%)
- Insider Sentiment: 30/100 (weight 10%)
- Analyst Consensus: 60/100 (weight 10%)
- Risk-Adjusted Return: 10/100 (weight 15%)
AEON Biopharma Inc opportunities and risks
What speaks for AEON
- ABP-450 biosimilar analytical validation
What speaks against AEON
- Imminent liquidity depletion and severe dilution
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| AEON | n/a | 0.0x | n/a | 0.0% | 0.0% | -158.8% |
| PHIO | n/a | 0.0x | n/a | 0.0% | 0.0% | -87.5% |
| GTBP | n/a | 0.0x | n/a | 0.0% | 0.0% | -151.0% |
| AKTX | n/a | 0.0x | n/a | 0.0% | 0.0% | -118.8% |
| PDSB | n/a | 0.0x | n/a | 0.0% | 0.0% | -58336.6% |
| APRE | n/a | 0.0x | 2.4x | 0.0% | 0.0% | -102.4% |
| Peer median | n/a | 0.0x | n/a | 0.0% | 0.0% | -118.8% |
Frequently asked questions about AEON Biopharma Inc (AEON)
Is AEON stock a good investment?
The cached TradeMates AI model rates AEON Biopharma Inc as AVOID with an investment score of 20/100. The model assesses AEON as an AVOID. Immediate cash insolvency risk and structural balance sheet impairment overpower biosimilar analytical milestones for ABP-450. This is algorithmic model output, not personal investment advice.
Is AEON stock a buy?
The TradeMates model verdict for AEON is AVOID with an investment score of 20/100. Treat this as a model signal to review, not a personal buy recommendation.